Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiao Yu, H Karl Greenblatt & David J Greenblatt. (2023) Designer benzodiazepines: an update. Expert Review of Clinical Pharmacology 16:2, pages 109-117.
Read now
Read now
Mark Haden, Josephine Cashman, Andrew Ketchin, Rebecca Macfarlane, Shabana Issa, Michael Eddleston, Selina Hines, Simon Hudson, Simon L. Hill & Simon H. L. Thomas. (2022) Detection of flubromazolam in patients with suspected non-medical drug use attending emergency departments in the United Kingdom. Clinical Toxicology 60:1, pages 33-37.
Read now
Read now
Joseph E. Carpenter, Brian Patrick Murray, Camille Dunkley, Ziad N. Kazzi & Melissa H. Gittinger. (2019) Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clinical Toxicology 57:4, pages 282-286.
Read now
Read now
Matilda Bäckberg, Madeleine Pettersson Bergstrand, Olof Beck & Anders Helander. (2019) Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project. Clinical Toxicology 57:3, pages 203-212.
Read now
Read now
Articles from other publishers (63)
Patrick J. Buckley, Neeta Shenai & Priya Gopalan. (2023) Designer Benzodiazepine Use in Pregnancy: A Case Report. Journal of the Academy of Consultation-Liaison Psychiatry 64:2, pages 194-195.
Crossref
Crossref
Eunchong Hong, Sun Mi Gu, Jin Mook Kim, Kyung Sik Yoon, Jin-Moo Lee, Young-Hoon Kim, Soo Kyung Suh, Dohyun Lee, Heejong Eom, Jaesuk Yun & Hye Jin Cha. (2022) The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents. Toxicology Research 11:4, pages 644-653.
Crossref
Crossref
Amber N. Edinoff, Catherine A. Nix, Amira S. Odisho, Caroline P. Babin, Alyssa G. Derouen, Salim C. Lutfallah, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye & Alan D. Kaye. (2022) Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects. Neurology International 14:3, pages 648-663.
Crossref
Crossref
Andrii Puzyrenko, Dan Wang, Randy Schneider, Greg Wallace, Sara Schreiber, Kristen Brandt & Ian L Gunsolus. (2022) Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC–QTOF-MS and LC–MS-MS. Journal of Analytical Toxicology 46:7, pages 712-718.
Crossref
Crossref
Jiang Ling, Wenqi Zhang, Xiaojun Yan, Wenlong Liu, Yanyan Wang & Yanjun Ding. (2022) Sensitive detection and primary metabolism analysis of flualprazolam in blood. Journal of Forensic and Legal Medicine 90, pages 102388.
Crossref
Crossref
A.W. Jones, F. Musshoff, T. Krämer, A. E. Steuer, D. Gerostamoulos, O.H. Drummer, G. Drasch, M. Balikova, J. Beyer, H. Teixeira, M. Thevis, W. Schänzer, H. Druid & G. Skopp. 2022. Handbook of Forensic Medicine. Handbook of Forensic Medicine
1167
1312
.
Michael Krämer, Sebastian Halter, Theresa Küting, Jennifer Liut, Burkhard Madea & Alexandra Maas. (2021) Neue psychoaktive SubstanzenNew psychoactive substances in emergency situations. Notfall + Rettungsmedizin 25:2, pages 137-146.
Crossref
Crossref
Shane Darke, Amy Peacock, Johan Duflou, Michael Farrell & Julia Lappin. (2022) Characteristics of fatal ‘novel’ benzodiazepine toxicity in Australia. Forensic Science International 331, pages 111140.
Crossref
Crossref
Sharon Essink, Johanna J. Nugteren-van Lonkhuyzen, Antoinette J.H.P. van Riel, Douwe Dekker & Laura Hondebrink. (2022) Significant toxicity following an increase in poisonings with designer benzodiazepines in the Netherlands between 2010 and 2020. Drug and Alcohol Dependence 231, pages 109244.
Crossref
Crossref
Michael Evans-Brown, Brendan Hughes & Roumen Sedefov. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
3
56
.
Arianna Giorgetti, Michaela J. Sommer, Maurice Wilde, Markus Große Perdekamp & Volker Auwärter. (2021) A case of fatal multidrug intoxication involving flualprazolam: distribution in body fluids and solid tissues. Forensic Toxicology 40:1, pages 180-188.
Crossref
Crossref
Lea Wagmann, Sascha K Manier, Christina Felske, Tanja M Gampfer, Matthias J Richter, Niels Eckstein & Markus R Meyer. (2021) Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam. Journal of Analytical Toxicology 45:9, pages 1014-1027.
Crossref
Crossref
Maurice Wilde, Volker Auwärter & Bjoern Moosmann. (2021) New psychoactive substances—Designer benzodiazepines. WIREs Forensic Science 3:6.
Crossref
Crossref
Matthew K. Laing, Lianping Ti, Allison Marmel, Samuel Tobias, Aaron M. Shapiro, Richard Laing, Mark Lysyshyn & M. Eugenia Socías. (2021) An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods. International Journal of Drug Policy 93, pages 103169.
Crossref
Crossref
Karolina Nowak & Piotr Adamowicz. (2021) Blood concentrations of new psychoactive substances belonging to benzodiazepine class. Forensic Toxicology 39:2, pages 377-384.
Crossref
Crossref
Pietro Brunetti, Raffaele Giorgetti, Adriano Tagliabracci, Marilyn Huestis & Francesco Busardò. (2021) Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals 14:6, pages 560.
Crossref
Crossref
Kathleen Rice, Laura Hikin, Alexander Lawson, Paul R Smith & Stephen Morley. (2021) Quantification of Flualprazolam in Blood by LC–MS-MS: A Case Series of Nine Deaths. Journal of Analytical Toxicology 45:4, pages 410-416.
Crossref
Crossref
Timothy P Rohrig, Kei A Osawa, Tyson R Baird & Kimberly B Youso. (2021) Driving Impairment Cases Involving Etizolam and Flubromazolam. Journal of Analytical Toxicology 45:1, pages 93-98.
Crossref
Crossref
Samuel Tobias, Aaron M. Shapiro, Cameron J. Grant, Priya Patel, Mark Lysyshyn & Lianping Ti. (2021) Drug checking identifies counterfeit alprazolam tablets. Drug and Alcohol Dependence 218, pages 108300.
Crossref
Crossref
Gunhild Heide, Gudrun Høiseth, Gerrit Middelkoop & Åse Marit Leere Øiestad. (2020) Blood Concentrations of Designer Benzodiazepines: Relation to Impairment and Findings in Forensic Cases. Journal of Analytical Toxicology 44:8, pages 905-914.
Crossref
Crossref
Ana Y Simão, Mónica Antunes, Hernâni Marques, Tiago Rosado, Sofia Soares, Joana Gonçalves, Mário Barroso, Maristela Andraus & Eugenia Gallardo. (2020) Recent bionalytical methods for the determination of new psychoactive substances in biological specimens. Bioanalysis 12:21, pages 1557-1595.
Crossref
Crossref
Owen Bowden-Jones & Dima Abdulrahim. 2020. Club Drugs and Novel Psychoactive Substances. Club Drugs and Novel Psychoactive Substances.
Kemba Abdul, Laura Hikin, Paul Smith, Hassan Kurimbokus, Emily Ashong, Lewis Couchman & Stephen R Morley. (2020) Flubromazolam: Detection in five post-mortem cases. Medicine, Science and the Law 60:4, pages 266-269.
Crossref
Crossref
Laura Orsolini, John M. Corkery, Stefania Chiappini, Amira Guirguis, Alessandro Vento, Domenico De Berardis, Duccio Papanti & Fabrizio Schifano. (2020) ‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports. Current Neuropharmacology 18:9, pages 809-837.
Crossref
Crossref
Lea Wagmann, Sascha K Manier, Thomas P Bambauer, Christina Felske, Niels Eckstein, Veit Flockerzi & Markus R Meyer. (2020) Toxicokinetics and Analytical Toxicology of Flualprazolam: Metabolic Fate, Isozyme Mapping, Human Plasma Concentration and Main Urinary Excretion Products. Journal of Analytical Toxicology 44:6, pages 549-558.
Crossref
Crossref
Karina Sommerfeld-Klatta, Magdalena Łukasik-Głębocka, Artur Teżyk, Paweł Panieński, Czesław Żaba & Barbara Zielińska-Psuja. (2020) Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration. Forensic Science International 310, pages 110237.
Crossref
Crossref
Nicole S. Jones & Jeffrey H. Comparin. (2020) Interpol review of controlled substances 2016–2019. Forensic Science International: Synergy 2, pages 608-669.
Crossref
Crossref
Heath A. Jolliff. 2020. Toxicology Cases for the Clinical and Forensic Laboratory. Toxicology Cases for the Clinical and Forensic Laboratory
291
293
.
Uttam Garg, Robert Krumsick, C. Clinton FrazeeIIIIII, Robert Pietak & Diane C. Peterson. 2020. Toxicology Cases for the Clinical and Forensic Laboratory. Toxicology Cases for the Clinical and Forensic Laboratory
117
119
.
Zhenhua Qian, Cuimei Liu, Jian Huang, Qingqing Deng & Zhendong Hua. (2019) Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case. Forensic Toxicology 38:1, pages 269-276.
Crossref
Crossref
Kavita Bhagat, Atamjit Singh, Suruchi Dhiman, Jatinder Vir Singh, Ramandeep Kaur, Gurinder Kaur, Harmandeep Kaur Gulati, Palwinder Singh, Raman Kumar, Rajan Salwan, Kajal Bhagat, Harbinder Singh, Sahil Sharma & Preet Mohinder Singh Bedi. (2019) Microwave-assisted synthesis of 11-substituted-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one derivatives catalysed by silica supported fluoroboric acid as potent antioxidant and anxiolytic agents. Medicinal Chemistry Research 28:12, pages 2200-2217.
Crossref
Crossref
Sabrina Lehmann, Alissa Sczyslo, Judith Froch-Cortis, Markus Alexander Rothschild, Mario Thevis, Hilke Andresen-Streichert & Katja Mercer-Chalmers-Bender. (2019) Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. Forensic Science International 303, pages 109959.
Crossref
Crossref
Evelyn S. Ligon, Jason Nawyn, Lonnie V. Jones, B. McKay Allred, Daniel V. ReinhardtJr.Jr. & Stefan France. (2019) Synthesis of Flubromazepam Positional Isomers for Forensic Analysis. The Journal of Organic Chemistry 84:16, pages 10280-10291.
Crossref
Crossref
Jolanta B. Zawilska & Jakub Wojcieszak. (2019) An expanding world of new psychoactive substances—designer benzodiazepines. NeuroToxicology 73, pages 8-16.
Crossref
Crossref
Luca Zamengo, Giampietro Frison & Guus Zwitser. (2018) Understanding and managing the new psychoactive substances phenomenon: a holistic approach. Journal of Public Health Policy 40:2, pages 217-235.
Crossref
Crossref
Kristin Bohnenberger & Mei T. Liu. (2019) Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil. Mental Health Clinician 9:3, pages 133-137.
Crossref
Crossref
Bjoern Moosmann, Philippe Bisel, Folker Westphal, Maurice Wilde, Jürgen Kempf, Verena Angerer & Volker Auwärter. (2019)
Characterization and
in vitro
phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'‐chlorodiazepam (Ro5–4864)
. Drug Testing and Analysis 11:3, pages 541-549.
Crossref
Crossref
Emma Partridge, Stephen Trobbiani, Peter Stockham, Cheryl Charlwood & Chris Kostakis. (2018) A Case Study Involving U-47700, Diclazepam and Flubromazepam—Application of Retrospective Analysis of HRMS Data. Journal of Analytical Toxicology 42:9, pages 655-660.
Crossref
Crossref
Kieran R. Manchester, Peter D. Maskell & Laura Waters. (2018)
Experimental versus theoretical log D
7.4
, pK
a
and plasma protein binding values for benzodiazepines appearing as new psychoactive substances
. Drug Testing and Analysis 10:8, pages 1258-1269.
Crossref
Crossref
Jeffrey D Pope, Kay Weng Choy, Olaf H Drummer & Hans G Schneider. (2018) Novel Benzodiazepines (Clonazolam and Flubromazolam) Identified in Candy-Like Pills. The Journal of Applied Laboratory Medicine 3:1, pages 48-55.
Crossref
Crossref
Elyse M. Cornett, Matthew B. Novitch, Andrew J. Brunk, Kelly S. Davidson, Bethany L. Menard, Richard D. Urman & Alan D. Kaye. (2018) New benzodiazepines for sedation. Best Practice & Research Clinical Anaesthesiology 32:2, pages 149-164.
Crossref
Crossref
Laura Waters, Kieran R. Manchester, Peter D. Maskell, Caroline Haegeman & Shozeb Haider. (2018) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Science & Justice 58:3, pages 219-225.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Markus R. Meyer, Olof Beck & Anders Helander. (2018) Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Testing and Analysis 10:3, pages 496-506.
Crossref
Crossref
Emil Chetraru, Alice Ameline, Laurie Gheddar, Jean-Sébastien Raul & Pascal Kintz. (2018) Les « designer benzodiazepines » : qu’en sait-on aujourd’hui ?. Toxicologie Analytique et Clinique 30:1, pages 5-18.
Crossref
Crossref
Bjoern Moosmann & Volker Auwärter. 2018. New Psychoactive Substances. New Psychoactive Substances
383
410
.
Kieran R. Manchester, Emma C. Lomas, Laura Waters, Fiona C. Dempsey & Peter D. Maskell. (2018) The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Testing and Analysis 10:1, pages 37-53.
Crossref
Crossref
Laura M. Huppertz, Bjoern Moosmann & Volker Auwärter. (2018) Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Testing and Analysis 10:1, pages 206-211.
Crossref
Crossref
Barry K. Logan, Amanda L.A. Mohr, Melissa Friscia, Alex J. Krotulski, Donna M. Papsun, Sherri L. Kacinko, Jeri D. Ropero-Miller & Marilyn A. Huestis. (2017) Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013–2016: A Review. Journal of Analytical Toxicology 41:7, pages 573-610.
Crossref
Crossref
Carolina Noble, Marie Mardal, Niels Bjerre Holm, Sys Stybe Johansen & Kristian Linnet. (2017)
In vitro
studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples
. Drug Testing and Analysis 9:8, pages 1182-1191.
Crossref
Crossref
Christian Brinch Mollerup, Petur Weihe Dalsgaard, Marie Mardal & Kristian Linnet. (2017) Targeted and non-targeted drug screening in whole blood by UHPLC-TOF-MS with data-independent acquisition. Drug Testing and Analysis 9:7, pages 1052-1061.
Crossref
Crossref
Pascal Kintz, Camille Richeval, Carole Jamey, Alice Ameline, Delphine Allorge, Jean-Michel Gaulier & Jean-Sébastien Raul. (2017) Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Testing and Analysis 9:7, pages 1026-1033.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
Martin Andersson & Anette Kjellgren. (2017) The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nordic Studies on Alcohol and Drugs 34:3, pages 217-229.
Crossref
Crossref
Liang Meng, Binling Zhu, Kefang Zheng & Shanlin Fu. (2017) Ultrasound-assisted low-density solvent dispersive liquid–liquid microextraction for the determination of 4 designer benzodiazepines in urine samples by gas chromatography–triple quadrupole mass spectrometry. Journal of Chromatography B 1053, pages 9-15.
Crossref
Crossref
Ariane Wohlfarth, Svante Vikingsson, Markus Roman, Mikael Andersson, Fredrik C. Kugelberg, Henrik Green & Robert Kronstrand. (2017) Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Science International 274, pages 55-63.
Crossref
Crossref
Jana Tomková, Martin Švidrnoch, Vítězslav Maier & Peter Ondra. (2017) Analysis of selected designer benzodiazepines by ultra high performance liquid chromatography with high-resolution time-of-flight mass spectrometry and the estimation of their partition coefficients by micellar electrokinetic chromatography. Journal of Separation Science 40:9, pages 2037-2044.
Crossref
Crossref
Madeleine Pettersson Bergstrand, Anders Helander, Therese Hansson & Olof Beck. (2017) Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Testing and Analysis 9:4, pages 640-645.
Crossref
Crossref
Pascal Kintz, Carole Jamey, Alice Ameline, Camille Richeval & Jean-Sébastien Raul. (2017) Characterization of metizolam, a designer benzodiazepine, in alternative biological specimens. Toxicologie Analytique et Clinique 29:1, pages 57-63.
Crossref
Crossref
Florent Brousse, Julie Deseille, Mathilde Ferdonnet, Alain Gond, Paul Lafargue, Bernard Marc & Jacques Raveneau. (2017) Drogues, les nouveaux produits de synthèse : nouveaux défis pour la santé et la sécurité publiques. Revue Francophone des Laboratoires 2017:489, pages 98-102.
Crossref
Crossref
Hannah R. Fudin, Jennifer L. Babin, Alisyn L. Hansen & Sidhartha D. Ray. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
31
55
.
Madeleine Pettersson Bergstrand, Anders Helander & Olof Beck. (2016) Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine. Journal of Chromatography B 1035, pages 104-110.
Crossref
Crossref
Gudrun H?iseth, Silja Skogstad Tuv & Ritva Karinen. (2016) Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Science International 268, pages 35-38.
Crossref
Crossref
Markus R. Meyer. (2016) New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Archives of Toxicology 90:10, pages 2421-2444.
Crossref
Crossref